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Abstract
Background: Population-based and longitudinal information regarding sexual risk behavior among patients with
multidrug resistant (MDR) HIV and their sexual partners is of great public health and clinical importance.
Objective: To characterize the HIV sexual risk behaviors of patients with and without drug-resistant HIV in the clinical
care setting over time.
Measurements: 393 HIV-positive patients completed questionnaires of self-reported sexual risk behaviors at
approximate 6-month intervals extending over 24 months. HIV viral load and genotypic drug resistance obtained during
the same time points were matched to the behavioral data. Multidrug resistance was defined as having resistance to 2 or
3 antiretroviral (ARV) drug classes.
Results: In serial cross-sectional analyses, 393 patients (44% female and 79% heterosexual) contributed 919 matched
behavioral and virologic results over the 24 months of data collection. Of these, 250 patients (64%) reported having sex
during at least 1 survey period resulting in greater than 10,000 sexual events with more than 1000 partners. Unprotected
sexual behavior was reported by 45% of sexually active patients, resulting in 34% of all sex events that exposed 29% of
all partners. Of these patients with unprotected sexual events, 31% had HIV drug resistance  11.6% with resistance to 2
classes of ARVs (2-class), and 1.8% with 3-class ARV resistance at the time of a sexual risk event. Close to 1000 or 28%
of all unprotected sexual events involved resistant strains (11% of these with resistance to 2 classes and 0.2% with 3-class
resistance, exposing 20% of unprotected sexual partners to resistant HIV (8% to 2-class and 0.6% to 3-class resistance).
In longitudinal analysis among the 78 patients who reported a cumulative total of 12 months of sexual history and had
resistance testing, 38% reported engaging in unprotected sexual behavior. There was substantial and complex variation
in the distribution of unprotected sexual events and in the detection of resistance over time.
Conclusion: In this study of HIV sexual risk and resistance over time among HIV-infected patients in clinical care, a
substantial proportion engaged in unprotected sex and had drug-resistant HIV, frequently exposing partners to 1- or 2-
class resistant HIV strains. However, relatively few exposures involved 3-class resistance. The dynamics of sexual risk
behavior and HIV drug resistance are complex and vary over time and urgently require both general and targeted
interventions to reduce transmission of resistant HIV.
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Introduction
The transmission of drug-resistant strains of HIV-1 to
newly infected persons is now a major clinical and public
health problem in developed countries with availability
of antiretroviral (ARV) therapy during the past decades. In
the United States, an estimated 10% to 15% of incident
HIV infections involve drug-resistant strains,[1-4] and
superinfection with resistant strains has been reported.[5-
7] Transmitted multidrug resistant (MDR) HIV-1 strains
that possess viral mutations that result in 2- or 3-class
drug resistance can profoundly affect the response to ARV
therapy.[1,2,8] The likelihood of transmission of MDR
HIV may not only depend on the HIV viral load and viral
fitness, but also on the frequency of risky behavioral expo-
sures to MDR strains.[9,10] Information on sexual risk
behavior among HIV-positive patients who may transmit
HIV with 2-class or 3-class drug resistance is of great pub-
lic health importance, but is currently very limited in the
published literature. Although important anecdotal and
cross-sectional information on sexual risk behavior of
patients with drug-resistant HIV is available,[8,11,12]
studies have generally not provided population-based
information over time on the quantitative aspects and
dynamics of the relationship of sexual risk and resistance.
The data needed to more fully understand this relation-
ship include: (1) cumulative proportion of patients with
MDR HIV strains who engage in unprotected sexual
behavior, (2) the number of sexual events involving such
individuals, and (3) the number of partners thereby
exposed to resistant strains.
We have previously performed and reported the baseline
results of the study of prevalence and predictors of HIV
drug resistance among HIV-positive patients in clinical
care who have engaged in sexual behaviors that may trans-
mit HIV to others.[9] To further characterize and extend
our understanding of this behavioral and biologic rela-
tionship, we now present cumulative and longitudinal
data on sexual risk involving MDR HIV over an approxi-
mate 2-year period in this HIV-infected clinic population.
Methods
Patient Population, HIV Sexual Risk Behavior, and HIV 
Drug Resistance
Patients were recruited from the 2 largest adult HIV clini-
cal care settings in Connecticut. Patients had been previ-
ously enrolled in a parent study  the Options Project  a
longitudinal intervention outcome study of HIV transmis-
sion risk in HIV-positive patients in clinical care.[9] The
HIV drug resistance and transmission risk substudy was
nested within the parent study and involved agreeing to
have a resistance test performed on archived plasma sam-
ples. A separate informed consent was obtained. Inclusion
criteria were written informed consent, at least 18 years
old, and healthy enough to complete the procedures. All
of the 497 patients enrolled in the Options Project were
offered participation in the resistance substudy. The study
was approved by the Institutional Review Boards at the
University of Connecticut, Hartford Hospital, and the
Human Investigations Committee at Yale University.
From 2000 to 2003, HIV-positive patients completed sur-
veys at approximate 6-month intervals via a computer-
administered self-interview of sexual risk behaviors dur-
ing the previous 3 months; the cumulative time covered
by the survey was 12 months over the approximate 24-
months of the study.[9,13] HIV viral load and HIV geno-
typic resistance data were obtained and matched to the
behavioral data by coded identifier as previously
described.[9,14] Patients were included if they had an HIV
viral load or a genotypic resistance test result within 3
months of a behavioral survey. Standard DNA sequencing
of the HIV-1 pol gene was used to detect HIV genotypic
resistance (ABI, Applied Biosystems, Foster City, Califor-
nia).[9,14] An HIV genotypic resistance test was per-
formed if the HIV viral load was > 400 HIV RNA copies/
mL.[9] Patients with a viral load of < 400 HIV RNA copies/
mL were classified as having a nondetectable viral load.
MDR resistance was defined as having major resistance
mutations to 2 or 3 antiretroviral drug classes (IAS-USA
2004 mutation table[15]).
Definitions of sexual behavior and unprotected sexual
behavior (sexual risk) were (1) no sexual behavior  no
vaginal, anal, or oral insertive sex events; (2) sexual behav-
ior and events  all vaginal, anal, and oral insertive sexual
events, protected (condom used) and unprotected; and
(3) unprotected sexual behavior and events: unprotected
vaginal, anal, and oral sexual events.
For the purposes of this study, sexual behavior was
defined as penile-vaginal and penile-anal intercourse for
women; penile-vaginal, penile-anal, and insertive penile-
oral sex for men who were HIV-positive, and who had
HIV-negative or status-unknown partners (oral-insertive
sex was restricted to HIV-negative or status-unknown part-
ners).[9]
Analysis and Statistical Methods
Analyses of the current data consisted of descriptive statis-
tics to quantify the total number of sexual events and pro-
portion of sexual events involving sexual risk, as well as
the total number and HIV sero-status of partners poten-
tially exposed, across the entire sample and specific to
those with known drug-resistant strains of HIV. These
quantities were derived and analyzed in 2 ways: (1) a
cross-sectional cohort, where all available observations
from all participants contributed to a single sample of
data; and (2) as a longitudinal sample where only those
contributing all 4 waves of data collection (4 time pointsJournal of the International AIDS Society 2005, 8:72 http://www.jiasociety.org/content/8/2/72
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with behavioral, resistance, and viral load data) were
included. All descriptive statistics and data management
procedures used SPSS version 11.01 (SPSS, Inc., Chicago,
Illinois).[16]
Results
Four hundred and four of the 497 Options Project
enrolled patients (81%) consented and enrolled in the
Options drug resistance and risk substudy. Of the 404
consented patients, 393 had a matched HIV genotypic
resistance test and behavioral survey result and were
included for analysis. Of these 393, 44% were female,
79% were heterosexual, 11% were men who had sex with
men, and 10% reported being bisexual. The mean age was
43 years; 38% were African American, 34% Hispanic, 22%
white, and 6% reported "other." Of the 393 patients, at
baseline 180 (46%) had an injection drug use history and
57 (14%) reported using injection drugs during the previ-
ous month. The mean duration of HIV infection was 8
years (median of 9 years) and duration of ARV therapy
was 23 years for those on ARV at baseline. The mean
CD4+ cell count at first survey was 414 cells/microliter
(mcL) (SD = 299 cells/mcL, median = 365 cells/mcL), and
48% had nondetectable HIV viral load. At least 263
patients were prescribed ARVs at the outset of the study. A
total of 919 matched data points consisting of both
behavioral and virologic data were available. Seventy-
eight patients contributed 4 matched behavioral and
resistance and viral load results obtained within the same
time period, 99 patients had 3, 94 had 2, and 122 contrib-
uted 1 matched result. As behavioral data were collected
for the preceding 3 months on multiple occasions, the
most complete matched population, those with 4
matched time points, represented 12 months of cumula-
tive sexual experience over an approximate 2-year period.
Total Sexual Events and HIV Drug Resistance
Of the 393 patients, 250 (64%) reported any sexual
behavior (protected or unprotected) during their partici-
pation in the study. These 250 patients reported a total of
10,116 sexual events with a maximum of 1225 partners.
Because assessments were collected over time and reports
of partners did not include any partner identifying infor-
mation, the number of partners across the study may have
included the same partner reported on multiple assess-
ments. If partners who are possibly redundant are
excluded (eg, if a patient reported risk events with 4 part-
ners at time 1 and 6 partners at time 2, a maximum
number of 6 partners was used, not 10), the total adjusted
number of sexual partners was 867.
Nine of the 250 patients (3.6%) who engaged in any sex-
ual behavior (protected or unprotected) had 3-class resist-
ance at the time of a sexual event, for a total of 242 sexual
events (2.4% of all sexual events) with an adjusted
number of 12 exposed partners (1% of all partners).
Unprotected Sex Events and HIV Drug Resistance
Of the 250 patients engaging in sexual behavior, 112
(45%) reported engaging in unprotected sex. These 112
patients with unprotected sexual risk engaged in 3476 risk
events (34% of all sex events), and exposed 354 partners
(252 of these (71%) were reported by the patients as
being HIV negative or status unknown). Of the 112
patients with sexual risk events, 60 (54%) had a viral load
above 1500 HIV RNA copies/mL at the time of the
reported unprotected sexual event (a viral load threshold
associated with greater risk of HIV transmission[17]),
cumulatively reporting a total of 1156 unprotected sex
events over the course of the study. Across these specific
sexual risk events, viral load at the time of the event
ranged from 1500 to 750,000; had a median of 27,420
and interquartile ranges (IQR) of 8417 (25th) to 103,439
(75th) HIV RNA copies/mL.
Of all of the patients reporting unprotected sex events, 35
(31%) had resistant virus at the time of 1 or more of their
risk events, 24 (21%) had only a single-class drug resist-
ance, 13 (11.6%) had 2-class only drug resistance, and 2
(1.8%) had a 3-class resistance at the time of a sexual
unprotected risk event (Figure 1). Note that resistant
patients engaging in risk often had viral loads that fluctu-
ated over time during the study but almost uniformly had
viral loads greater than the 1500 HIV RNA copy threshold
associated with transmission risk at the time of the risk
event. For this group median viral load across the reported
transmission risk events was 14,244 copies/mL (IQR of
6410 25th] to 750,000 [75th]).
Of the 3476 total reported unprotected sexual events, 978
(28%) involved ARV-resistant strains; 577 (16.6%) risk
events involved a single-class resistance, 393 (11%)
Sexual risk events and HIV drug resistance Figure 1
Sexual risk events and HIV drug resistance.
Patients Engaging in
Sexual Risk: 112
45% (112/250) of all
patients having sex
35 (31%) patients
had HIV drug resistance
13 (11.6%) had
2-class resistance
2 (1.8%) patients
had 3-class resistance
978 (28%) unprotected
sex events involved
resistance
71 (20%) sex partners
exposed to resistance
393 (11%) involved
2-class resistance
29 (8%) exposed to
2-class resistance
2 (0.6%) exposed to
3-class resistance
8 (0.2%) involved
3-class resistance
Sexual Risk Events:
3476
34% (3476/10,116) of all
sex events
Partners Exposed:
354
29% (354/1225) of all
sexual partners
At the time of the sexual risk eventJournal of the International AIDS Society 2005, 8:72 http://www.jiasociety.org/content/8/2/72
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involved 2-class, and 8 risk events (0.2%) 3-class resist-
ance. Seventy-one of 354 (20%) sexual risk partners were
exposed to resistant HIV with 29 (8%) exposed to 2-class
resistance and 2 (0.6%) exposed to 3-class resistance. Of
the 71 partners exposed to drug-resistant HIV, 59 (83%)
were reported by the patient as being HIV negative or sta-
tus unknown. If possible redundant partners are excluded,
58 partners or 21% of all adjusted total partners (273)
were exposed to drug resistance. Of these 58 partners
exposed to drug-resistant virus, 47 (81%) were reportedly
HIV negative or status unknown.
The prevalence of specific resistance mutations in patients
engaging in sexual risk can be found in Table 1 and the
resistance patterns of the viral strains from the 2 patients
engaging in sexual risk with 3-class resistance are listed in
Table 2.
Longitudinal Results in Patients With 4 Behavioral Surveys 
and Resistance Results
Recognizing that both sexual risk behaviors and resistance
might change over time, we sought to provide a more
complete picture of sexual transmission risk and drug
resistance dynamics over time by analyzing the 78
patients (20% of total population) with 4 surveys, viral
load, and matched resistance data. This subset of the pop-
ulation provided a cumulative total of 12 months of sex-
ual behavior experience over time. Sixty-six of the 78
(85%) patients engaged in vaginal, anal, or oral insertive
sexual behavior during the 12-month cumulative period
and reported a total of 3034 sexual events (median, 24/
patient; range, 1427). Patients with resistance at the time
of a sexual event contributed 549 sexual events (18% of
all events). Patients had 3-class drug resistance during 62
or 2% of these sexual events. Thirty of the 78 patients
(38%) engaged in unprotected vaginal, anal, or oral inser-
tive sex at some time during the study, resulting in 789
sexual transmission risk events (median, 1/patient; range,
1131) exposing 70 partners (adjusted for redundancy;
median, 1/patient; range, 115). As can be seen in Figure 2,
there is a wide variation and uneven distribution in sexual
risk events among the 30 patients. In addition, this wide
variation extends to differences in sexual risk events with
resistant and sensitive strains and numbers of partners
exposed. For example, 3 patients contributed 7% (48/
655) of the unprotected sex events with wild type virus
and 74% (99/134) of the unprotected risk events that
occurred with resistant strains.
The dynamics of risk and resistance were complex and var-
ied over time. Patients had transitions in the viral resist-
ance genotype (eg, from 1-class resistance to 2-class
resistance, to nondetectable viral load or wild type virus)
as patients went on new regimens or were taken off drugs,
and some patients went in and out of sexual risk during
their course of participation in the study. Risk behavior
could be matched with confirmed viral load and viral
resistance results within the specified time for 78 patients.
Focusing on sexual transmission risk events involving
resistance, 9 of the 78 patients (12%) had drug resistance
at the time of unprotected sexual risk behavior and
engaged in 134 (17%) of all unprotected sexual risk
events. These 9 patients exposed 19 (27%) of all partners
to drug-resistant virus (Figure 2). Of the unprotected sex
events, 89 (11%) involved 2-class resistance and 7 (1%)
involved 3-class resistance. Ten sexual risk partners (14%)
Table 1: HIV Genotypic Resistance Mutations for Patients Engaging in Sexual Risk
Antiretroviral Class Resistance and Number of Patients With Resistance Mutation* and % of Patients With a Mutation
Nucleoside reverse transcriptase inhibitor (N = 29) 215Y/F/C/S/D (79%)
184V (52%)
41L (34%)
219Q/E (34%)
70R (28%)
67N (10%)
74V (3%)
151M (3%)
69SSS (3%)
Nonnucleoside reverse transcriptase inhibitor (N = 15) 103N (53%)
181C (40%)
190A/S (38%)
Protease inhibitor (N = 16) 90M (50%)
82A/F/D (31%)
30N (20%)
84V (6%)
48V (6%)
*Only major mutations are listed.Journal of the International AIDS Society 2005, 8:72 http://www.jiasociety.org/content/8/2/72
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were exposed to 2-class resistance and 1 (1.4%) to 3-class
resistance during these unprotected events.
Assuming the partners for each patient were the same at
all other time points, the minimum number of partners
exposed (adjusted number) was 43; if all partners were
different, the maximum number of partners exposed was
70. Using 70 and 43 separately as denominators to create
conservative and more liberal estimates of proportion of
partners exposed to ARV resistance, the percent of total
partners exposed to 3-class resistance ranged from 1.4%
(1/70) to 2.3% (1/43). The percent of partners exposed to
any type of resistance ranged from 27% (19/70) to 30%
(13/43).
Discussion
In this study of a diverse population of HIV-positive
patients in clinical care, we obtained serial cross-sectional
population-based data on the number of unprotected sex-
ual events involving drug-resistant strains of HIV, and the
number of partners potentially exposed to these resistant
strains over time. In addition, in a subset of patients fol-
lowed longitudinally, with matched biologic and behav-
ioral data, we documented 12 months of reported
cumulative unprotected sexual behavior over a period of
observation of approximately 2 years. Both cross-sectional
and longitudinal data from this diverse HIV-positive pop-
ulation receiving care indicate that those with drug-resist-
ant HIV had a substantial amount of continued
unprotected sexual risk behavior that could result in HIV
transmission. In addition to the risk of HIV transmission
in general, it is of further concern that during the time
period in which the unprotected sexual events took place,
approximately 11% of total risk events and 9% of the part-
ners involved in these events were exposed to MDR HIV.
It is of some comfort to note that in this sample, most
were 2-class resistance and only approximately 1% of
patients, events, and partners involved 3-class resistant
strains.
These data are unique and help provide a more complete
picture of the risk of drug resistance transmission via sex-
ual risk behavior among patients with HIV infection and
provide insight into the growing rate of drug resistance in
incident HIV infections in areas where ARVs has been
available for several decades.
In our previous baseline cross-sectional survey of risk
behaviors in this population, approximately 23% of
patients reported unprotected sexual behavior during a
single 3-month period.[9] By capturing longitudinal
behavioral data over the ensuing time period of approxi-
mately 2 years, 38% of patients who reported 12 months
of cumulative sexual history engaged in unprotected sex at
some time during the study. This is a larger proportion
than that reported in previous single time point cross-sec-
tional and nonquantitative resistance and risk stud-
ies,[9,12,18] and makes it clear that patients' sexual
behavior is not static and changes over time. Some
patients moved in and out of unprotected sexual risk
behaviors at different times.
The majority of sexual risk partners (71%) involved in
unprotected sexual events reported by this sample of HIV-
positive patients in clinical care were HIV-negative or HIV
serostatus unknown. Furthermore, of the sexual risk part-
ners exposed to resistant strains, 83% were reported as
being HIV negative or serostatus unknown. This suggests
that in this predominately heterosexual population
serosorting, or choosing partners of the same HIV serosta-
tus, among patients with resistance who engaged in risk
behaviors occurred at a low frequency.
One of the most interesting findings in this study is the
wide variability in distribution of sexual risk in the popu-
lation. The number of individuals engaging in risk behav-
iors, sexual risk events, and partners exposed were all
unevenly distributed. Relatively few patients contributed
a large number of unprotected sex events with drug-resist-
Table 2: HIV Resistance Genotypes of the 2 Patients With 3-Class Antiretroviral Drug Resistance at the time of the Sexual Risk 
Events
Patient Engagingin Sexual 
Risk
CD4+ Cell Count and HIV 
Viral Load
HIV Genotype # Unprotected Sexual Events
(# penile-vaginal or anal) 
[Partners exposed]
White Female IDU 429 cells/mcL
10,400 HIV RNA copies/mL
PI-46L, 82A
NNRTI-103N
RTI-41L, 184V, 210W, 215Y, 
219Q
7 (7)
[1]
Black Male MSM 51 cells/mcL
75,000 HIV RNA copies/mL
PI-10I, 46L, 54L, 71V, 82A
NNRTI  181C, 190A
RTI-67N, 210W, 215Y, 219N
1 (1)
[1]
IDU = injection-drug user; mcL = microliter; PI = protease inhibitor; NNRTI-nonnucleoside reverse transcriptase inhibitor; NRTI = reverse 
transcriptase inhibitor; MSM = man who has sex with men.Journal of the International AIDS Society 2005, 8:72 http://www.jiasociety.org/content/8/2/72
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ant strains. This was particularly apparent in the sample of
78 patients who were followed longitudinally and had 12
months of sexual history matched with resistance data. In
this subset of patients, 9 carried resistant virus and
engaged in unprotected sex, with unprotected events rang-
ing from 3 to 79, and exposed partners from 1 to 7 per
patient. Furthermore, among these patients, 3 contributed
85% of the unprotected sex events involving resistant
virus. Some patients exposed many partners in the 12-
month period but with few unprotected events, whereas
other patients exposed a single partner with many unpro-
tected events. It is apparent from these data that not all
patients or partners confer or receive similar transmission
risk and, importantly, in this patient population, it
appears that there is a small core group of individuals who
contribute a large proportion of the sexual transmission
risk events with resistant virus.
The opportunity to follow a subset of the patients longitu-
dinally has enabled us to document that HIV-positive
patients in this study had transitions over time in their
predominant detectable viral genotype from 1-class to 2-
class or 3-class resistance or back to a nondetectable viral
load or to wild type virus (in concert with initiating new
regimens or discontinuing medications). Along with the
variations in transmission risk over time, this illustrates
the dynamic process at the interface of drug resistance and
unprotected sexual risk behavior (both persistent as well
as intermittent).[12,18-22] The associations between
overall sexual behavior, unprotected sex, and HIV drug
resistance are complex and dynamic and further studies
are needed to better elucidate these interrelationships
over time.
In this study, all risk groups were represented and the
demography and risk profile was that typical for HIV
clinic populations in inner city urban areas of the north-
eastern United States where the HIV/AIDS epidemic is
mature.[23] Notably, women, non-whites and heterosex-
ual and intravenous drug users were most prominent in
this population. One limitation of the study is that men
who have sex with men were underrepresented and there-
fore characteristics and dynamics related to risk and resist-
ance that may differ in this population may have been
undetected. In addition, our study results may only be
characteristic of the geographic region  urban northeast-
ern United States  studied or the period when assessments
were collected. They are, however, quite consistent with
the small but growing data from other regions and popu-
lations,[9,18,22,24] where men who have sex with men
were well represented.[12] Moreover, these data are of
pressing clinical and public health importance, and war-
rant similar and additional investigation in different pop-
ulations and geographic areas.
An additional limitation in the current study was our ina-
bility to identify and test partners of the patients for HIV
infection to determine incident rates of transmission of
resistant viruses. This would have enabled us to explore
actual transmission rates rather than risk of resistant virus
transmission from the clinic population. Such an effort
was beyond the scope of this study. Furthermore, the
study provided strict assurances of confidentiality to the
participants and would have required participants to
divulge information that in some areas in the United
States is considered a criminal offense.[25] We used
standard DNA sequencing to detect resistance mutations
and such methods are limited in their ability to detect
minor resistant viral variants in a sample. Thus, we may
have underestimated resistant transmission risk events
that could have involved minor resistant populations that
were not detected with standard methods.
Distribution and relationship of unprotected sexual events;  antiretroviral resistance and partners exposed among 30  patients engaging in sexual risk followed longitudinally in clin- ical care Figure 2
Distribution and relationship of unprotected sexual 
events; antiretroviral resistance and partners 
exposed among 30 patients engaging in sexual risk 
followed longitudinally in clinical care. Thirty patients 
engaging in unprotected sex during a cumulative total of 12 
months: Cumulative number of unprotected sex events rep-
resented in bars, number of unprotected events with resist-
ance (red stripe) and without (solid blue), and total number 
of partners exposed for all unprotected sex events for each 
patient (in column below each patient number). Cumulative 
unprotected sexual events (n = 789; median number of 
events = 11 [range 1131]), unprotected sex events with 
resistance (n = 134), and number of partners exposed (n = 
70). Over the 4 three-month time periods, patients had back-
and-forth transitions in the viral resistance genotype (eg, 
from 1-class resistance to 2-class resistance, or back to non-
detectable viral load or wild-type virus (as patients received 
new regimens or were taken off drugs). In addition, some 
patients moved in and out of unprotected sexual risk during 
these time periods. Note that 7 patients provided 72% of 
unprotected risk events (patients 17) and 3 patients provided 
85% of unprotected sexual risk events with resistant virus.
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It is not known presently if the transmission of MDR HIV
strains will continue to increase over time. If transmission
risk behaviors remain stable over time in a population but
drug resistance as a result of therapeutic failure develops
in more patients, the total transmission events involving
MDR strains may increase. Patients in care with and with-
out resistant strains are only 1 portion of those who trans-
mit HIV; however, those in care are more likely to carry
resistant strains because of ARV exposure and longer dura-
tion of therapy. Alternatively, the transmission of resist-
ance strains may decrease if more patients remain off
drugs for longer periods or if they undergo monitored
structured treatment interruptions and wild type virus pre-
dominates. Furthermore, future antiretroviral therapy that
is more potent and easier to take may lead to lower viral
load levels and decreased viral fitness.
Results from this study suggest that a likely major source
of new resistant infections is a core group of patients
within the clinic setting itself who have both resistance
and ongoing unprotected HIV sexual transmission risk
behaviors. Additionally, because many and likely increas-
ing numbers of patients with or without drug-resistant
strains engaging in sexual risk behavior are followed in
clinical care, targeted prevention and risk reduction strat-
egies situated within the clinical care setting may be an
effective critical addition to HIV prevention efforts. Risk
reduction strategies targeting HIV-positive patients in gen-
eral and particularly those with highest potential for trans-
mission of resistant HIV are a central component of
current HIV prevention recommendations.[23] This issue
takes on additional timeliness and relevance as growing
populations of patients with HIV in resource-limited set-
tings begin to receive ARV therapy and before resistance
transmission becomes widespread.[26]
The findings of this study support the development, test-
ing, and deployment of targeted prevention and risk
reduction strategies in the clinical care setting, where ARV
resistance is present among the patient population contin-
uing to engage in behaviors that may transmit HIV, and
prevention strategies may benefit from the frequent con-
tacts and trusting relationships that occur between clini-
cians and their patients.[23,26,27]
Presented in part at the XIV International HIV Drug Resist-
ance Workshop, Quebec City, Quebec, Canada, June 711,
2005. Abstract 127.
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